nVerses Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

nVerses Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-400	Closed	-$28.1K	–	120
2024 Q3	$28.1K	Buy	+400	New	+$33.4K	0.01%	752

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

nVerses Capital's BMRN Position: Q4 2024 in Review

nVerses Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 400 shares — an estimated $28.1K sold.

nVerses Capital first reported a position in BMRN in Q3 2024 and held it in 1 quarter. The position peaked at $28.1K in Q3 2024. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

nVerses Capital reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 400 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $28.1K.
nVerses Capital first reported a position in BioMarin Pharmaceuticals in Q3 2024 and held it in 1 quarter.
nVerses Capital's BioMarin Pharmaceuticals position peaked at $28.1K in Q3 2024.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.